BeiGene Ltd. ADR (BGNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
BGNE POWR Grades
- Growth is the dimension where BGNE ranks best; there it ranks ahead of 83.77% of US stocks.
- The strongest trend for BGNE is in Stability, which has been heading up over the past 179 days.
- BGNE ranks lowest in Momentum; there it ranks in the 4th percentile.
BGNE Stock Summary
- BEIGENE LTD's market capitalization of $22,518,775,496 is ahead of 90.81% of US-listed equities.
- BGNE's price/sales ratio is 15.9; that's higher than the P/S ratio of 93.46% of US stocks.
- With a year-over-year growth in debt of -14.1%, BEIGENE LTD's debt growth rate surpasses only 19.13% of about US stocks.
- Stocks that are quantitatively similar to BGNE, based on their financial statements, market capitalization, and price volatility, are EA, GNTX, FBIO, TDUP, and APM.
- BGNE's SEC filings can be seen here. And to visit BEIGENE LTD's official web site, go to www.beigene.com.
BGNE Valuation Summary
- In comparison to the median Healthcare stock, BGNE's price/earnings ratio is 151.33% lower, now standing at -11.6.
- BGNE's price/sales ratio has moved down 49.7 over the prior 87 months.
Below are key valuation metrics over time for BGNE.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BGNE | 2023-03-17 | 16.4 | 5.3 | -11.6 | -9.9 |
| BGNE | 2023-03-16 | 16.6 | 5.3 | -11.7 | -10.0 |
| BGNE | 2023-03-15 | 17.4 | 5.6 | -12.3 | -10.6 |
| BGNE | 2023-03-14 | 17.0 | 5.5 | -12.0 | -10.4 |
| BGNE | 2023-03-13 | 16.4 | 5.3 | -11.6 | -9.9 |
| BGNE | 2023-03-10 | 15.9 | 5.1 | -11.3 | -9.6 |
BGNE Growth Metrics
- Its 4 year price growth rate is now at 330.2%.
- Its 3 year net income to common stockholders growth rate is now at -159.78%.
- The year over year cash and equivalents growth rate now stands at 128.56%.
The table below shows BGNE's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 1,249.805 | -1,686.267 | -2,148.932 |
| 2022-06-30 | 1,068.617 | -1,620.074 | -2,005.231 |
| 2022-03-31 | 877.037 | -1,660.381 | -1,914.123 |
| 2021-12-31 | 1,176.283 | -1,298.723 | -1,413.354 |
| 2021-09-30 | 1,062.404 | -1,123.218 | -1,300.446 |
| 2021-06-30 | 947.044 | -973.746 | -1,311.815 |
BGNE's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BGNE has a Quality Grade of C, ranking ahead of 25.08% of graded US stocks.
- BGNE's asset turnover comes in at 0.168 -- ranking 211th of 681 Pharmaceutical Products stocks.
- AADI, CPIX, and NAVB are the stocks whose asset turnover ratios are most correlated with BGNE.
The table below shows BGNE's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.168 | 0.883 | -0.377 |
| 2021-03-31 | 0.165 | 0.897 | -0.358 |
| 2020-12-31 | 0.065 | 0.771 | -0.552 |
| 2020-09-30 | 0.070 | 0.746 | -0.678 |
| 2020-06-30 | 0.078 | 0.704 | -0.890 |
| 2020-03-31 | 0.166 | 0.826 | -0.893 |
BGNE Stock Price Chart Interactive Chart >
BGNE Price/Volume Stats
| Current price | $219.02 | 52-week high | $280.62 |
| Prev. close | $215.65 | 52-week low | $118.18 |
| Day low | $217.51 | Volume | 65,600 |
| Day high | $224.05 | Avg. volume | 239,070 |
| 50-day MA | $241.95 | Dividend yield | N/A |
| 200-day MA | $193.40 | Market Cap | 22.85B |
BeiGene Ltd. ADR (BGNE) Company Bio
BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. Founded in Beijing in 2010 by Xiaodong Wang and chief executive officer John V. Oyler, the company has offices in China, the United States, Australia and Europe. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor which became the first cancer drug developed in China to gain approval from the U.S. Food and Drug Administration when it received accelerated approval to treat mantle cell lymphoma in November 2019. (Source:Wikipedia)
Latest BGNE News From Around the Web
Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidatehttps://cdn.benzinga.com/files/images/story/2023/03/17/lptx.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Leap Therapeutics Inc (NASDAQ: LPTX) announced BeiGene Ltd's (NASDAQ: BGNE) option under the Exclusive Option, and License Agreement granting rights in certain Asian territories to DKN-01 has expired. The companies announced an option agreement in January 2020 for DKN-01 in Asia (excluding Japan), Australia, and New Zealand. Leap and BeiGene will continue collaborating on Part C of the |
Prelude (PRLD) Collaborates With BeiGene for Oncology CandidatePrelude Therapeutics (PRLD) and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients. |
HKMA monitoring Silicon Valley Bank fallout as Hong Kong-listed firms' exposure reaches US$217 millionThe fallout from the implosion of Silicon Valley Bank (SVB) has reached Hong Kong's shores, prompting the local monetary authority to assure depositors that the city's banking system is sufficiently protected from the second major collapse of a US bank since 2008. At least 13 Hong Kong-listed technology and biotech firms have deposits totalling US$217.23 million at SVB, with amounts ranging from US$400,000 to US$175.5 million. Meanwhile, SVB's Hong Kong office in Jardine House was empty on Monda |
Tencent, Alibaba, AIA fuel Hong Kong market rally while BeiGene erases loss amid Silicon Valley Bank falloutHong Kong stocks advanced amid a bullish view on earnings among Chinese tech leaders, overshadowing concerns about a wider fallout among Chinese biotech companies including BeiGene from the collapse of Silicon Valley Bank. HSBC gained after buying the UK unit of the US bank. The Hang Seng Index rose 2 per cent to 19,695.97 at the close of Monday trading, while the Tech Index surged 2.9 per cent and the Shanghai Composite Index added 1 per cent. The city's benchmark index slumped 6.1 per cent las |
Q4 2022 Zymeworks Inc Earnings CallQ4 2022 Zymeworks Inc Earnings Call |
BGNE Price Returns
| 1-mo | -3.55% |
| 3-mo | -3.12% |
| 6-mo | 57.98% |
| 1-year | 8.20% |
| 3-year | 69.43% |
| 5-year | 38.61% |
| YTD | -0.42% |
| 2022 | -18.82% |
| 2021 | 4.85% |
| 2020 | 55.88% |
| 2019 | 18.18% |
| 2018 | 43.53% |
Continue Researching BGNE
Want to see what other sources are saying about BeiGene Ltd's financials and stock price? Try the links below:BeiGene Ltd (BGNE) Stock Price | Nasdaq
BeiGene Ltd (BGNE) Stock Quote, History and News - Yahoo Finance
BeiGene Ltd (BGNE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...